Date

Attendees

Committee MemberPresentAbsent
X
X
Warren KibbeX
X
Gregory TawaX
William Hendriks
X
Matthew Breen
X
Roel VerhaakX



Goals

Outstanding Action items

Agenda

Discussion ItemWhoNotes
Data submission request from Iowa State
New data submission request from PRECINCT
  • "Novel teatments for Diffuse large B cell lymphoma (DLBCL) in dogs"
  • Data Submission Folder: DLBCL
Data submission approved by Senior Advisory Committee
  • "Immune Pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma" 
  • Data Submission Folder: OSA-Normal
  • Onboarding meeting set up with submitters
  • Study will be called OSA02
  • New program for Colorado State
PRECINCT Data Request Submission: Inhaled IL-15 Immunotherapy for Treatment of Lung Metastases

All

Review of other Modiano publications: Other Modiano Publication Considerations.xlsx
Study Updates
  • TCL01
    • Still working on loading the data into our environments
  • PRECINCT01
    • Waiting on actual data files from UC Davis group
  • PANCAN01 (15 TB Re-analysis)
    • Submitter PoC identified 
  • OSA02
    • Dawn & Sunetra are working on the template-driven data submission

Minutes (Not Verbatim)

**Voting for Iowa State submission, only samples that have RNA-Seq data for Bladder Cancer and Healthy individuals**

In favor: Greg, Erika, Roel, Warren


**Questions answered from email sent to submitters on 10//22**

  1. The ICDC is comprised of cases of spontaneous arising cancer in canines. Is there some implied linkage between thyroid tumors and IBD?
  2. How many of the 100 animals were controls?
  3. Is there any molecular data available for these subjects or tissues?
  4. The submission request form mentions 5 manuscripts being written based on the data, are any of these genomics or proteomics studies with molecular-level data?
  5. Is there any clinical metadata available for these subjects (breed, age, sex, disease)?

**Questions answered from email sent to submitters on 10/13/22**

  1. How many of the canine patient samples will ultimately have omics data associated with them?
  2. Are metadata available for the cancer-related samples?
  3. Are the organoids validated and are they available for other researchers?
  4. Is there a long-term plan to have genomic coverage for all individuals?
  5. Will these data be made accessible to the public in any other repository?

**Q&A Session**

  1. Will screening data be available in the future?
  2. Are there publications?
  3. Will the organoids be made available to other researchers?
  4. As a researcher interested in testing a particular compound...
  5. How do other labs reproduce research on the organoids?
    1. There is a paper coming out that gives exact specifications, collaborations are possible, but the organoids would stay at Iowa State. Open to colloabortions with industry and academia.